Physicians' Academy for Cardiovascular Education

SGLT2 inhibition and cardiovascular outcomes: lessons from recent clinical trials

10' education - May 21, 2016 - ESC HF 2016, Florence, Italy - David Fitchett, MD - University of Toronto, ONT, Canada

Video navigation menu

  • EMPA-REG Outcome - the first CV endpoint trial of SGLT2-inhibition 0:18
  • Effect of empagliflozin on HbA1c, BP, weight and hematocrit 3:46
  • The reduction in the 3-point MACE with empagliflozin vs. placebo is mainly driven by reduced CV mortality 4:40
  • Heart failure outcomes with empagliflozin in EMPA-REG Outcome 7:21
  • Outcomes in patients with heart failure at baseline 9:09
  • Adverse events in EMPA-REG Outcome 11:21
  • Overall clinical benefit of empagliflozin 11:58

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: